# Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

> **NCT02623920** · PHASE2 · WITHDRAWN · sponsor: **University of Arizona**

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Mediastinal Large B-cell Lymphoma
- Grey Zone Lymphoma
- High Grade B Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Brentuximab
- **DRUG:** Bendamustine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02623920
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-12-16
- **Primary completion:** 2017-05-17
- **Final completion:** 2017-05-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study prior to enrollment of any patients.
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623920, "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02623920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*